Skip to main content
OpenTrials

Clinical trial condition

Parotid Diseases

Explore clinical trials studying Parotid Diseases. Study availability and eligibility vary by location and protocol.

85 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Parotid Diseases trial results

Completed

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744

Conditions
Infections, Measles, Measles-Mumps-Rubella Vaccine, +15 more
Locations
  • GSK Investigational Site Tuscaloosa, Alabama, United States
  • GSK Investigational Site Conway, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
View all 48 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

NCT01621802

Conditions
Infections, Measles, Measles-Mumps-Rubella, +12 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Benton, Arkansas, United States
View all 67 locations
View Trial Details
Completed

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

NCT01702428

Conditions
Infections, Measles, Mononegavirales Infections, +14 more
Locations
  • GSK Investigational Site Dothan, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Anaheim, California, United States
View all 90 locations
View Trial Details
Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175

Conditions
Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tuscaloosa, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 141 locations
View Trial Details
Completed

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

NCT01506193

Conditions
Chickenpox, DNA Virus Infections, Herpesviridae Infections, +19 more
Locations
  • GSK Investigational Site Rome, Lazio, Italy
  • GSK Investigational Site Chiavari, Liguria, Italy
  • GSK Investigational Site Genoa, Liguria, Italy
  • GSK Investigational Site Milan, Lombardy, Italy
View all 13 locations
View Trial Details

Related conditions